An Unusual Presentation of Gaucher Disease in an Infant With Progressive Dyspnea

REFERENCES

1. ↵
   1. Kliegman RM,
   2. Behrman RE,
   3. Jenson HB,
   4. Stanton BF

   (2007) Nelson Textbook of Pediatrics. 18th ed (Saunders; Philadelphia, PA) eds.
2. ↵
   1. Cooper GM

   The Cell: A Molecular Approach. 2nd ed, Lysosomes (Sinauer Associates; 2000, Sunderland, MA) In, http://www.ncbi.nlm.nih.gov/books/NBK9953. Accessed March 27, 2013.
3. ↵
   1. Shebani E,
   2. Johannesson M,
   3. Strömberg B,
   4. Roomans GM

   (2, 2003) A patient with type 2 Gaucher's disease with respiratory disease. J Pediatr 142(2):209–210, pmid:12584549.

   OpenUrlPubMed
4. ↵
   1. Mistry PK,
   2. Abrahamov A

   (12, 1997) A practical approach to diagnosis and management of Gaucher's disease. Baillieres Clin Haematol 10(4):817–838, pmid:9497866.

   OpenUrlCrossRefPubMed
5. ↵
   1. Connock M,
   2. Burls A,
   3. Frew E,
   4. et al.

   (7, 2006) The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review. Health Technol Assess 10(24):iii–iv, ix–136.

   OpenUrlPubMedWeb of Science
6. ↵
   1. Cox T,
   2. Lachmann R,
   3. Hollak C,
   4. et al.

   (4 29, 2000) Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355(9214):1481–1485, pmid:10801168.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Moyses C

   (5 29, 2003) Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Philos Trans R Soc Lond B Biol Sci 358(1433):955–960, pmid:12803929.

   OpenUrlAbstract/FREE Full Text